[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-rich-plasma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-rich-plasma":227},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,72,98,134,164,193,215,239,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641341","evaluation-of-the-efficacy-and-safety-of-using-platelet-rich-fibrin-prf-based-lipobolus-for-the-immediate-reconstruction-of-defects-after-breast-conserving-resection-for-breast-cancer-minimally-invasive-primary-immediate-grafting-100641341",false,"NCT07658170","Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)","MINIPIG","Inclusion Criteria:\n\n* Histologically verified breast cancer (BC).\n* Disease stage from cTis to cT2 according to the TNM classification (AJCC, 8th edition).\n* Tumor grade G1 or G2.\n* Estrogen receptor positivity (ER+).\n* ECOG performance status = 0.\n* Primary tumor size up to 2 cm, based solely on preoperative examination data (mammography, ultrasound, MRI).\n* Indications for breast-conserving surgery (BCS) with a breast resection extent determined by a multidisciplinary oncology board.\n* Submission of an informed voluntary consent (IVC) regarding participation in the study.\n* Ability to understand and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n* Male gender.\n* ECOG ≥ 1.\n* Multifocal or multicentric tumor.\n* Grade G3.\n* Triple-negative or HER2-positive tumor with uncontrolled disease.\n* Stage cT3 or higher or distant metastases (M1).\n* Inflammatory breast cancer.\n* Prior neoadjuvant chemotherapy or hormonal therapy.\n* Prior radiation therapy to the breast.\n* Presence of blood coagulation disorders (coagulopathy, thrombocytopathy, thrombocytopenia \\\u003C 100 × 10⁹\u002FL).\n* Taking anticoagulants or antiplatelet agents that cannot be temporarily discontinued.\n* Presence of active infectious diseases.\n* Acute autoimmune diseases.\n* Decompensated comorbidities (diabetes mellitus, cardiovascular diseases, etc.).\n* Body mass index (BMI) \\\u003C 18.5 kg\u002Fm² (insufficient adipose tissue volume for liposuction).\n* Pregnancy or lactation.\n* Mental illnesses that prevent informed consent.\n* Known allergy to local anesthetics or sodium citrate.","FEMALE","18 Years","69 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors, which may help the graft survive better.\n\nThe main questions it aims to answer are:\n\nWhat percentage of the fat graft's volume remains in place 3 months after radiation therapy?\n\nWhat is the safety of this procedure, including its side effects and any impact on cancer returning?\n\nParticipants will:\n\n* Undergo standard breast-conserving surgery to remove the tumor\n* Have liposuction (fat removal) from their own belly or thighs\n* Receive a \"lipobolus\" (their own fat mixed with PRF) placed into the breast defect during the same surgery\n* Follow up for 12 months with ultrasound scans, physical exams, and questionnaires (BREASTQ) about their satisfaction and quality of life",[27,28,29,30],"Breast Cancer","Lipofilling","Fat Graft","Platelet Rich Plasma","RECRUITING","2026-06-14",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":35},"2025-11-13",{"date":39,"type":21},"2028-06-03",{"name":41,"class":42},"The Leningrad Regional Clinical Hospital","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100442290","efficacy-at-one-year-of-combined-injections-of-plasma-rich-in-platelets-and-hyaluronic-acid-in-knee-osteoarthritis-100442290","NCT05039463","Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis","ISPAG","Inclusion Criteria:\n\n* age : \\> 18 years old\n* Patients benefiting, in the context of knee osteoarthritis, from viscosupplementation alone or from two injections of PRP, in combination with HA, at the Amiens University Hospital.\n\nExclusion Criteria:\n\n* Patient refusal to use the data\n* Language barrier\n* Age less than 18 years old.","ALL",{"count":53,"type":21},100,"OBSERVATIONAL","The French Society of Rheumatology cannot rule on the value of intra-articular injections of PRP due to the lack of hindsight and insufficient data. In fact, the injection protocols are very heterogeneous in terms of preparation method, the presence or not of leukocytes, the number of centrifugations, the volume injected, the ultrasound guidance, which makes it difficult to analyze the literature. The investigator objective is therefore to evaluate the effectiveness of combined injections of PRP and hyaluronic acid.",[57,58,30],"Knee Osteoarthritis","Hyaluronic Acid",[60,61,57],"platelet rich plasma","hyaluronic acid","2026-06-12",{"date":64,"type":35},"2026-06-15",{"date":66,"type":35},"2021-08-16",{"date":68,"type":21},"2026-06",{"name":70,"class":71},"Centre Hospitalier Universitaire, Amiens","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100630722","phase-4-pilot-exploration-of-platelet-characterization-of-platelet-rich-plasma-created-by-two-different-systems-100630722","NCT07491367","Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems","PRP-PEPC","Inclusion Criteria:\n\n* Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis\n* Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee\n* Will be able to attend and perform physical therapy\n\nExclusion Criteria:\n\n* Received injection therapy for knee osteoarthritis in the past 6 months\n* Have severe arthritis diagnosed in ≥1 major joint by radiology criteria\n* History of septic arthritis\n* Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)\n* Have had high tibial osteotomy, partial knee replacement, patellar resurfacing, total knee replacement, or have existing surgical hardware in the knee\n* Received a platelet-rich plasma injection elsewhere in the body within the past 3 months\n* Have a platelet disorder or bleeding disorder\n* Have a rheumatologic disease, autoimmune disorder, immunocompromised status, or active history of cancer\n* Are taking chemotherapy, require regular prednisone, or require regular anti-inflammatory use\n* Are pregnant, breastfeeding, or unwilling to practice birth control during the study\n* If both knees have osteoarthritis and the other knee has KL score equal to or greater than 2.\n* Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training",{"count":80,"type":21},20,[82],"PHASE4","The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.",[85,86,30,87],"Knee Osteoarthristis","Cartilage Damage","Platelet Rich Plasma Injection","NOT_YET_RECRUITING","2026-06-08",{"date":91,"type":35},"2026-06-09",{"date":93,"type":21},"2026-07-01",{"date":95,"type":21},"2028-09",{"name":97,"class":71},"University of California, San Francisco",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100627987","experimental-study-on-the-use-of-intrauterine-infusion-of-autologous-platelet-rich-plasma-prgf-iui-in-patients-with-recurrent-implantation-failure-andor-refractory-thin-endometrium-100627987","NCT07455773","Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium","PMA_PREPAIRE STUDY: Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium.","PMA_PREPAIRE","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years\n* Body mass index (BMI) between 18 and 30 kg\u002Fm\n* Undergoing assisted reproductive technology (ART) cycle with hormone replacement therapy\n* Endometrial thickness \\\u003C 7 mm after at least 10 days of hormone replacement therapy\n* History of at least one failed embryo transfer\n* Normal hematologic and biochemical laboratory results\n* Ability to understand and sign written informed consent\n\nExclusion Criteria:\n\n* Endometrial hyperplasia or uterine malignancy\n* Active pelvic inflammatory disease or untreated sexually transmitted infection\n* Coagulation disorders or platelet abnormalities\n* Thrombocytopenia (\\\u003C100,000\u002Fmm³)\n* Chronic anticoagulant therapy\n* Active systemic infection or immunodeficiency\n* Contraindications to intrauterine procedures","45 Years",{"count":108,"type":21},80,[24],"Endometrial receptivity is a key determinant of success in assisted reproductive technology (ART). A significant proportion of patients experience repeated implantation failure despite euploid embryos and adequate laboratory conditions. Thin endometrium, often defined as ultrasound-measured thickness \\\u003C7 mm at embryo transfer, is frequently refractory to estrogen therapy and associated with low implantation and clinical pregnancy rates.\n\nPlatelet-Rich Plasma (PRP), obtained from autologous blood by double centrifugation, is rich in growth factors capable of stimulating cell proliferation, angiogenesis, and tissue regeneration, suggesting potential benefits for endometrial function. Preliminary studies indicate improved endometrial thickness and reproductive outcomes following intrauterine PRP infusion, but standardized protocols and systematic data are lacking.\n\nThe PMA\\_PREPAIRE study is a prospective, single-center, controlled, non-randomized interventional clinical trial conducted at the Reproductive Medicine Center of Cardinal Massaia Hospital, Asti. The study aims to evaluate the efficacy and safety of intrauterine infusion of autologous platelet-rich plasma (PRP), in association with hormone replacement therapy (HRT), in improving endometrial receptivity and reproductive outcomes in women with thin or refractory endometrium. The study includes a prospective control group treated with standard HRT alone.\n\nEligible women will be treated with standard clinical care, with PRP infusion offered to those with insufficient response to HRT. Inclusion criteria include age 18-45, BMI 18-30 kg\u002Fm², history of ≥1 failed embryo transfer, EMT \\\u003C5 mm after ≥10 days of HRT, and normal routine lab tests. Exclusion criteria include endometrial disease, recent gynecological infection, and systemic conditions such as thrombocytopenia or coagulopathies.\n\nProcedures include standard HRT from cycle days 1-2, serial ultrasound monitoring of endometrial thickness from days 6-8, intrauterine PRP infusion if EMT ≤7 mm (up to three infusions per cycle), embryo transfer once EMT ≥7 mm, and follow-up through pregnancy testing and confirmatory ultrasound.\n\nCollected data will be analyzed using descriptive statistics, paired and unpaired comparative analyses, and multivariate logistic regression models to evaluate predictors of treatment response and reproductive outcomes (significance level p \\\u003C 0.05).\n\nA sample size of 34 patients per group was estimated to detect a 1.5 mm difference in endometrial thickness (EMT) with 90% statistical power. Considering an anticipated dropout rate of 15%, a total of 40 patients per group will be enrolled.\n\nThe study includes:\n\nan intervention group consisting of 40 patients treated with HRT plus intrauterine PRP infusion; a prospective control group consisting of 40 patients with refractory thin endometrium treated with standard HRT alone, without PRP.",[112,113,114,115,116,117],"Recurrent Implantation Failure","Endometrial Receptivity Disorders","Embryo Implantation","Platelet-Rich Plasma","Platelet-rich Plasma (PRP)","Infertility, Female",[119,120,121,122,123,124],"Endometrial receptivity","Recurrent implantation failure","Assisted reproductive technology","Platelet-rich plasma","Intrauterine infusion","Autologous biological therapy","2026-05-12",{"date":127,"type":35},"2026-05-14",{"date":129,"type":21},"2026-05-01",{"date":131,"type":21},"2027-12",{"name":133,"class":42},"Azienda Sanitaria Locale di Asti",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":43},"100620022","prp-plus-fractional-co-laser-for-acne-scars-100620022","NCT07352215","PRP Plus Fractional CO₂ Laser for Acne Scars","Evaluating the Effectiveness of Platelet-Rich Plasma as an Adjunct to Fractional Carbon Dioxide Laser Therapy in Improving Facial Acne Scar Appearance: A Randomized Controlled Trial","PRPLT","Inclusion Criteria:Adults aged 18 to 40 years\n\nMale and female participants\n\nFitzpatrick skin types I to V\n\nPresence of moderate-to-severe acne scars\n\nWilling to undergo 3 treatment sessions and follow-up visits\n\nAble to provide informed consent -\n\nExclusion Criteria:Use of topical anti-acne medications in the past 1 month\n\nHistory of keloid formation or hypertrophic scarring\n\nActive acne or active skin inflammation at treatment area\n\nDiabetes mellitus\n\nPhotosensitive disorders (e.g., lupus, dermatomyositis)\n\nMelasma\n\nActive infections (e.g., Herpes simplex)\n\nRecent laser resurfacing or similar procedures\n\nOutdoor workers with high sun exposure\n\nVitiligo\n\nPregnancy or breastfeeding\n\nBleeding disorders or anticoagulant therapy\n\nUnrealistic expectations or inability to comply with follow-up\n\n\\-","40 Years",{"count":144,"type":21},70,[24],"This randomized controlled trial aims to evaluate whether adding platelet-rich plasma (PRP) to fractional CO₂ laser resurfacing improves the treatment of moderate-to-severe acne scars compared with laser alone. Seventy adults aged 18-40 years will be recruited from the Dermatology Department of Gujranwala Medical College Teaching Hospital. Participants will be randomly assigned to receive either fractional CO₂ laser combined with topical PRP or fractional CO₂ laser alone, with three treatment sessions delivered four weeks apart.\n\nThe primary outcome is the change in acne scar severity measured using the Goodman and Baron Quantitative Acne Scar Scale. Secondary outcomes include redness, edema, pain scores, and patient satisfaction assessed using Likert and numeric rating scales. The study is single-blinded, with patients unaware of treatment allocation. PRP will be prepared using a standardized double-spin centrifugation process. Data will be analyzed using appropriate statistical tests with a significance level of p \\\u003C 0.05. The study aims to determine whether PRP enhances laser efficacy, reduces side effects, and improves patient-reported outcomes.",[148,149,115],"Post-Acne Atrophic Scars","Carbon Dioxide Lasers",[151,152,153,154],"Post-acne Scarring","Fractional CO₂ Laser","PRP Therapy","Skin Resurfacing","2026-01-11",{"date":157,"type":35},"2026-01-20",{"date":159,"type":35},"2025-10-31",{"date":161,"type":21},"2026-04-30",{"name":163,"class":71},"Gujranwala medical college District Headquarters Hospital, Gujranwala",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100594523","phase-4-allogeneic-vs-autologous-prp-for-diabetic-wounds-in-renal-dysfunction-a-randomized-controlled-trial-100594523","NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial","Comparing Allogeneic Versus Autologous Platelet-Rich Plasma for Diabetic Wound Healing in Patients With Renal Dysfunction：a Randomized Controlled Trial","Inclusion Criteria:\n\n1. The patient is aged 18-80 years old;\n2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;\n3. Abnormal renal function defined as:\n\n   * Serum creatinine \\>106 μmol\u002FL (men) or \\>97 μmol\u002FL (women)\n   * AND eGFR \\\u003C90 mL\u002Fmin\u002F1.73m² (CKD-EPI) ；\n4. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;\n5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met\\*;\n6. Voluntarily sign an informed consent form;\n\nExclusion Criteria:\n\n1. Blood glucose is out of control or not yet effectively controlled，;\n2. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n3. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；\n4. Uncontrolled systemic or disseminated infections;\n5. Patients with advanced malignant tumors;\n6. Pregnant or lactating women；\n7. The patient is unable to cooperate or has mental disorders;\n8. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.","80 Years",{"count":173,"type":21},56,[82],"Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.",[177,30,178,179],"Diabetic Wounds","Allogeneic Blood Transfusions","Renal Dysfunction",[181,30,182,183],"Diabetic wounds","allogeneic blood","renal dysfunction","2025-08-23",{"date":186,"type":35},"2025-08-26",{"date":188,"type":21},"2026-04",{"date":190,"type":21},"2028-05",{"name":192,"class":71},"Peking University Third Hospital",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":43},"100587674","efficacy-and-safety-of-pulsed-radiofrequency-combined-with-platelet-rich-plasma-to-treat-idiopathic-glossopharyngeal-neuralgia-gpn-100587674","NCT06931457","Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet Rich Plasma to Treat Idiopathic Glossopharyngeal Neuralgia (GPN)","Efficacy and Safety of the Application of Pulsed Radiofrequency, Combined With Platelet Rich Plasma, to the Treatment of Idiopathic Glossopharyngeal Neuralgia (GPN): A Study Protocol for a Multi-Center, Prospective, Open-Label, Propensity Score Match Cohort Study","Inclusion Criteria:\n\n1. age \\>18 years;\n2. diagnosed with idiopathic GPN according to the third International Classification of Headache Disorders (ICHD) classification;\n3. patients who failed pharmacotherapy or intolerable side effects of medication;\n4. undergoing PRF for GPN;\n5. at least 1 month of follow-up recordings.\n\nExclusion Criteria:\n\n1. Patients with bilateral GPN;\n2. Abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiography or chest radiography;\n3. Infection at the puncture site;\n4. Previous mental illness;\n5. Previous history of narcotic drug abuse;\n6. Prior anticoagulant or antiplatelet therapy;\n7. An implantable pulse generator;\n8. Current pregnancy or breast feeding.\n9. Patients with incomplete medical records (lack of baseline data or postoperative follow-up data).",{"count":201,"type":21},121,"To investigate the efficacy and safety of the application of PRF combined PRP to the for the treatment of GPN.",[204,205,30],"Glossopharyngeal Neuralgia","Pulsed Radiofrequency","2025-07-01",{"date":208,"type":35},"2025-07-03",{"date":210,"type":35},"2025-05-01",{"date":212,"type":21},"2027-06-01",{"name":214,"class":71},"Beijing Tiantan Hospital",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":171,"enrollmentInfo":222,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":43},"100476415","compare-vaginal-estrogen-and-platelet-rich-plasma-over-women-with-genitourinary-syndrome-of-menopause-100476415","NCT05483634","Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Inclusion Criteria:\n\n* Women with menopause\n* Patients with symptoms of genitourinary syndrome of menopause\n\nExclusion Criteria:\n\n* Genitourinary bleeding or infection without definitive diagnosis\n* Coagulopathy\n* Allergy to medication or therapy related with the treatment\n* Chronic disease that might influence outcome\n* Using medication that might influence outcome in 30 days\n* Using hormone or steroid within 8 weeks",{"count":223,"type":21},40,"The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.\n\nThe treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.",[226,227,228,229],"Menopause","Platelet-rich Plasma","Estrogen Replacement Therapy","Vaginal Atrophy","2025-05-06",{"date":232,"type":35},"2025-05-09",{"date":234,"type":21},"2025-12-01",{"date":236,"type":21},"2027-06-30",{"name":238,"class":71},"Mackay Memorial Hospital",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":43},"100553909","the-efficacy-and-safety-of-pulsed-radiofrequency-combined-with-platelet-rich-plasma-for-infraorbital-neuralgia-100553909","NCT06492213","The Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet-rich Plasma for Infraorbital Neuralgia","Effectiveness and Safety of Platelet-Rich Plasma Combined With Pulsed Radiofrequency to Treat Patients With Infraorbital Neuralgia","Inclusion Criteria:\n\n1. Age between 18 to 75 years;\n2. Paroxysmal or persistent stabbing pain in the distribution area of the infraorbital nerve and positive response to diagnostic block (1 ml of 2% lidocaine) prior to treatment;\n3. NRS score≥7;\n4. Scheduled for PRF treatment for IONa；\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Platelet count \\\u003C105\\*109\u002FL, ongoing anticoagulation therapy or antiplatelets treatment, coagulation disorders or bleeding disorders;\n2. Severe cardiopulmonary or hepatorenal dysfunction;\n3. Infection at the puncture site; .\n4. Neuralgia secondary to tissue damage around the infraorbital foramen from causes such as maxillary sinusitis or tumor;\n5. History of destructive treatments such as radiofrequency thermocoagulation, chemical ablation, infraorbital neurectomy, infraorbital nerve avulsion, etc;\n6. History of mental disorders；\n7. History of narcotic drug abuse;\n8. Unable to cooperation.","75 Years",{"count":248,"type":21},240,"This is a multicenter, prospective, observational, propensity score matching, cohort, and assessor-blinded study designed to compare the effectiveness and safety of PRP injections combined with PRF treatment with PRF alone in patients with IONa who are responded poorly to conventional therapies and are reluctant to receive destructive therapies for seeking a better minimally invasive treatment strategy.",[251,227],"Infraorbital Neuralgia",[253],"Infraorbital neuralgia; platelet- rich plasma","2025-02-19",{"date":256,"type":35},"2025-02-21",{"date":258,"type":35},"2024-07-01",{"date":260,"type":21},"2027-07-01",{"name":214,"class":71},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":43},"100543664","microfracture-with-platelet-rich-plasma-gel-injection-for-osteochondral-lesion-of-the-talus-100543664","NCT06358807","Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus","Clinical Efficacy of Arthroscopic Microfracture Combined With Local Injection of Platelet Rich Plasma Gel in Treatment of Osteochondral Lesion of the Talus: A Randomized Control Trial","Inclusion Criteria:\n\n* Chronic ankle pain, diagnosed as osteochondral lesion of the talus;\n* Lesion size ≤ 1.5 cm2 or the diameter of the lesion ≤ 1.5 cm;\n* Conservative treatment of at least 3 months fails to relieve symptoms;\n* Willingness to voluntarily participate in the trial and to sign informed consent.\n\nExclusion Criteria:\n\n* Varus or valgus deformity of the ankle of more than 5 degrees;\n* Grade III injury of the lateral collateral ligament of ankle;\n* Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.);\n* Joint fibrosis, stiffness, and significantly restricted range of motion;\n* Evidence of moderate to severe knee osteoarthritis on plain radiographs;\n* Failure to complete the rehabilitation protocol as required;\n* Patient medically not fit for surgery, radiographs or MRI;\n* For women, pregnant, planning to be pregnant or lactating.","60 Years",{"count":144,"type":21},[24],"The goal of this clinical trial is to learn if combined local injection of platelet rich plasma (PRP) gel adds clinical efficacy to isolated arthroscopic microfracture in treatment of osteochondral lesion of the talus (OLT). The interface integration of the injured area will also be assessed via radiographic follow-up. The main questions it aims to answer are:\n\n* Does arthroscopic microfracture combined with PRP gel injection improve ankle function of participants based on American Orthopedic Foot and Ankle Society (AOFAS) Score?\n* Does arthroscopic microfracture combined with PRP gel injection improve interface integration of the injured cartilage on magnetic resonance imaging (MRI)? Researchers will compare arthroscopic microfracture with concomitant local injection of PRP gel to isolated microfracture to see if intraoperative PRP gel injection adds clinical efficacy to isolated arthroscopic microfracture in treatment of OLT.\n\nParticipants will:\n\n* Undergo either isolated arthroscopic microfracture or microfracture with intraoperative injection of PRP gel\n* Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment\n* Take MRI preoperatively and 6, 12 and 24 months after surgery",[274,275,30],"Osteochondral Lesion of Talus","Microfractures",[274,275,30,277,278],"Arthroscopic Techniques","Clinical Efficacy","2024-05-17",{"date":281,"type":35},"2024-05-20",{"date":283,"type":35},"2024-01-01",{"date":285,"type":21},"2026-12-31",{"name":192,"class":71}]